MarketBeat on MSN

Amylyx Pharmaceuticals eyes phase 3 AVEXITIDE readout as 2027 launch comes into focus

3 small-cap biotechs with potential breakthroughs in 2024 Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal ...
Benzinga.com

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), noting the company is poised to open post-bariatric hypoglycemia’s (PBH) blockbuster potential. PBH is a ...